+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA))), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs (NSAIDs)), End User - Forecast 2024-2030- Product Image
Global Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA))), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs (NSAIDs)), End User - Forecast 2024-2030- Product Image
Sale

Global Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA))), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs (NSAIDs)), End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 180 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924702
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Axial Spondyloarthritis Market size was estimated at USD 5.32 billion in 2023, USD 5.68 billion in 2024, and is expected to grow at a CAGR of 7.42% to reach USD 8.79 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Axial Spondyloarthritis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Axial Spondyloarthritis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Axial Spondyloarthritis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Eli Lilly and Company, Galapagos NV, Inmagene Biopharmaceuticals, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A.

Market Segmentation & Coverage

This research report categorizes the Axial Spondyloarthritis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Ankylosing Spondylitis (AS)
    • Non-Radiographic Axial Spondyloarthritis (nr-axSpA))
  • Drug Class
    • Anti-Rheumatic Drugs
    • Glucocorticoids
    • Non-steroidal anti-inflammatory Drugs (NSAIDs)
  • End User
    • Academic Research Institutes
    • Clinics
    • Hospital
    • Rehabilitation Center
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Axial Spondyloarthritis Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Axial Spondyloarthritis Market?
  3. What are the technology trends and regulatory frameworks in the Axial Spondyloarthritis Market?
  4. What is the market share of the leading vendors in the Axial Spondyloarthritis Market?
  5. Which modes and strategic moves are suitable for entering the Axial Spondyloarthritis Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Axial Spondyloarthritis Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of arthritis and joint pain
5.1.1.2. Growing number of research and development activities
5.1.1.3. Efforts by government and private players to expand treatment options for arthritis
5.1.2. Restraints
5.1.2.1. Incidences of product and drug recall
5.1.3. Opportunities
5.1.3.1. Advances in personalized care for axial spondyloarthritis
5.1.3.2. Emergence of novel biologic agents targeting axial spondyloarthritis
5.1.4. Challenges
5.1.4.1. Stringent regulations concerning the drug approval process
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Axial Spondyloarthritis Market, by Type
6.1. Introduction
6.2. Ankylosing Spondylitis (AS)
6.3. Non-Radiographic Axial Spondyloarthritis (nr-axSpA))
7. Axial Spondyloarthritis Market, by Drug Class
7.1. Introduction
7.2. Anti-Rheumatic Drugs
7.3. Glucocorticoids
7.4. Non-steroidal anti-inflammatory Drugs (NSAIDs)
8. Axial Spondyloarthritis Market, by End User
8.1. Introduction
8.2. Academic Research Institutes
8.3. Clinics
8.4. Hospital
8.5. Rehabilitation Center
9. Americas Axial Spondyloarthritis Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Axial Spondyloarthritis Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Axial Spondyloarthritis Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. Amgen Inc.
13.1.4. Eli Lilly and Company
13.1.5. Galapagos NV
13.1.6. Inmagene Biopharmaceuticals
13.1.7. Johnson & Johnson Services, Inc.
13.1.8. Merck & Co., Inc.
13.1.9. Novartis AG
13.1.10. Pfizer Inc.
13.1.11. UCB S.A.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. AXIAL SPONDYLOARTHRITIS MARKET RESEARCH PROCESS
FIGURE 2. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2023 VS 2030
FIGURE 3. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. AXIAL SPONDYLOARTHRITIS MARKET DYNAMICS
FIGURE 7. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 12. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANKYLOSING SPONDYLITIS (AS), BY REGION, 2018-2030 (USD MILLION)
TABLE 7. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)), BY REGION, 2018-2030 (USD MILLION)
TABLE 8. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 9. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANTI-RHEUMATIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 13. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. AXIAL SPONDYLOARTHRITIS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Inmagene Biopharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.68 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.79 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Axial Spondyloarthritis Drugs Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Axial Spondyloarthritis Drugs Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 83 Pages
  • Global
From
Axial Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 - Product Image

Axial Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

  • Report
  • 112 Pages
  • Global
From
Axial Spondyloarthritis - Pipeline Insight, 2024 - Product Image

Axial Spondyloarthritis - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Non-Radiographic Axial Spondyloarthritis (nrAxSpA) - Pipeline Insight, 2024 - Product Image

Non-Radiographic Axial Spondyloarthritis (nrAxSpA) - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Global Osteoarthritis Pain Drug Market by Drug Class (Corticosteriods, NSAIDs, Viscosupplementation), Route of Administration (Oral, Parenteral, Topical), Distribution Channel - Forecast 2024-2030 - Product Image

Global Osteoarthritis Pain Drug Market by Drug Class (Corticosteriods, NSAIDs, Viscosupplementation), Route of Administration (Oral, Parenteral, Topical), Distribution Channel - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From

About the Axial Spondyloarthritis Drug Market

Axial Spondyloarthritis (axSpA) is a type of inflammatory arthritis that affects the spine and sacroiliac joints. It is a chronic, progressive condition that can cause pain, stiffness, and swelling in the affected areas. Immune Disorders Drugs are used to treat axSpA, as they help to reduce inflammation and pain. These drugs can be taken orally, injected, or infused, depending on the severity of the condition. Commonly used drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids. The Axial Spondyloarthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of axSpA, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.